Parkinson's Disease Inflammatory Biomarker Profiling

Inclusion Criteria All Participants * Subjects must be willing and able to participate in study * Subjects must be willing and able to provide written consent to participate. * Subjects must be willing and able to comply with scheduled clinic visits and study procedures (UPDRS exam, blood draw and complete a questionnaire) * Subjects are not currently taking an immunomodulatory (e.g. anti- tumor necrosis factor (TNF), immunosuppressants/stimulants) agent in the past 90 days * No active or recent (\< 3 weeks) infection requiring clinical intervention and/or pharmaceutical treatment or febrile neutropenia within the last week. * 18-89 years old Parkinson's Disease Patients * Clinical diagnosis of PD by a movement disorders specialist consistent with standard criteria * Able to attend a clinical visit in the 'off' state * Hoehn and Yahr stage I-IV Caregiver Controls • Individuals without PD who share environmental exposures (i.e. spouses, children, caregivers or other individuals who frequently spend significant time (\>6 hours) in proximity to the PD subject) OR age and sex matched healthy individuals from general population Exclusion Criteria All Participants * Unstable cardiopulmonary or cerebrovascular disease * Renal disease or failure w/ serum creatinine greater than 2.5 * Severe or unstable depression or other axis I psychopathology * Epilepsy * Prior brain surgery related to PD (DBS, cell implantation, gene therapy, etc.) * Severe head injury with evidence of brain injury * Essential Thrombocythemia (ET) (\>450,000 platelets/mL) * Patients currently being treated with any of the following, within the past 5 days: * Immunomodulatory agents (e.g. Remicade®, Humira®, Enbrel®) (within the past 90 days) * Corticosteroids * Probenecid® * Coenzyme Q10® * Anticoagulants